Biologic Switching in Patients with Severe Asthma: Effects on Exacerbations, Corticosteroid Use and Lung Function.

J Clin Med · 2026 · PMC13258676 · PMID 42279010

Europe PMC DOI

hedged sentence

0.0630

closest p · 1.3× alpha

0.0630

boldest claim

The sentences

did not reach statistical significancep = 0.063so close (0.05 < p ≤ 0.1)

In both groups, a reduction was observed in the number of patients receiving high-dose ICS–LABA therapy; however, this change did not reach statistical significance in either the omalizumab to mepolizumab group ( p = 0.063) or the mepolizumab to benralizumab group ( p = 0.250).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.